argenx NV ADR (ARGX)vsATAI Life Sciences BV (ATAI)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
ATAI
ATAI Life Sciences BV
$7.35
0.00%
HEALTHCARE · Cap: $2.70B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 132178% more annual revenue ($5.92B vs $4.47M). ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
ATAI
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Margin of Safety
+62.5%
Fair Value
$10.60
Current Price
$7.35
$3.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Revenue surging 137.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
Trading at 15.3x book value
0.0% margin — thin
ROE of -378.0% — below average capital efficiency
Earnings declined 96.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : ATAI
The strongest argument for ATAI centers on Revenue Growth, Debt/Equity. Revenue growth of 137.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ATAI
The primary concerns for ATAI are Price/Book, Profit Margin, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while ATAI is a hypergrowth play — different risk/reward profiles.
ATAI carries more volatility with a beta of 1.55 — expect wider price swings.
ATAI is growing revenue faster at 137.0% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 28/100), backed by strong 31.7% margins and 52.1% revenue growth. ATAI offers better value entry with a 62.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
ATAI Life Sciences BV
HEALTHCARE · BIOTECHNOLOGY · USA
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?